263 related articles for article (PubMed ID: 32296928)
1. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
[TBL] [Abstract][Full Text] [Related]
2. DNA flow cytometric analysis of paraffin-embedded tissue for the diagnosis of malignancy in bile duct biopsies.
Lee H; Rabinovitch PS; Mattis AN; Kakar S; Choi WT
Hum Pathol; 2020 May; 99():80-87. PubMed ID: 32272125
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutational status in bile duct adenomas and hamartomas.
Pujals A; Bioulac-Sage P; Castain C; Charpy C; Zafrani ES; Calderaro J
Histopathology; 2015 Oct; 67(4):562-7. PubMed ID: 25704541
[TBL] [Abstract][Full Text] [Related]
4. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor.
Oda E; Yamamura K; Hara Y; Matsumura K; Akahoshi S; Yuki H; Motohara T; Miyamoto H; Kinoshita K; Matsumura F; Ohnishi K; Komohara Y; Beppu T
Anticancer Res; 2021 Oct; 41(10):5249-5254. PubMed ID: 34593478
[TBL] [Abstract][Full Text] [Related]
7. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.
Tsokos CG; Krings G; Yilmaz F; Ferrell LD; Gill RM
Hum Pathol; 2016 Nov; 57():61-67. PubMed ID: 27396933
[TBL] [Abstract][Full Text] [Related]
8. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma arising in bile duct adenoma with focal area of bile duct hamartoma.
Hasebe T; Sakamoto M; Mukai K; Kawano N; Konishi M; Ryu M; Fukamachi S; Hirohashi S
Virchows Arch; 1995; 426(2):209-13. PubMed ID: 7757293
[TBL] [Abstract][Full Text] [Related]
10. An assessment of risk factors for recurrence and survival for patients undergoing liver resection for intrahepatic cholangiocarcinoma.
Öztürk NB; Jamil LH
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):766-774. PubMed ID: 38683193
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
12. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
13. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Hornick JL; Lauwers GY; Odze RD
Am J Surg Pathol; 2005 Mar; 29(3):381-9. PubMed ID: 15725808
[TBL] [Abstract][Full Text] [Related]
15. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.
Sapisochin G; Facciuto M; Rubbia-Brandt L; Marti J; Mehta N; Yao FY; Vibert E; Cherqui D; Grant DR; Hernandez-Alejandro R; Dale CH; Cucchetti A; Pinna A; Hwang S; Lee SG; Agopian VG; Busuttil RW; Rizvi S; Heimbach JK; Montenovo M; Reyes J; Cesaretti M; Soubrane O; Reichman T; Seal J; Kim PT; Klintmalm G; Sposito C; Mazzaferro V; Dutkowski P; Clavien PA; Toso C; Majno P; Kneteman N; Saunders C; Bruix J;
Hepatology; 2016 Oct; 64(4):1178-88. PubMed ID: 27481548
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of sarcomatoid change in patients with intrahepatic cholangiocarcinoma and prognosis after surgical liver resection: A Propensity Score Matching analysis.
Wang T; Kong J; Yang X; Shen S; Zhang M; Wang W
J Surg Oncol; 2020 Mar; 121(3):524-537. PubMed ID: 31867746
[TBL] [Abstract][Full Text] [Related]
18. DNA analysis of cholangiocarcinoma cells: prognostic and clinical importance.
Abou-Rebyeh H; Al-Abadi H; Jonas S; Rotter I; Bechstein WO; Neuhaus P
Cancer Detect Prev; 2002; 26(4):313-9. PubMed ID: 12430636
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
Yang G; Zong H
Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
[TBL] [Abstract][Full Text] [Related]
20. Challenges of surgical management of intrahepatic cholangiocarcinoma.
Squires MH; Cloyd JM; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):671-681. PubMed ID: 29911912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
